Key takeaway: Shilpa Medicare Limited's investor presentation for the quarter ended June 30, 2026, reported a revenue of INR 469 crores, reflecting a 43% year-over-year increase, and an EBITDA of INR 139 crores, up 42% year-over-year. The presentation highlighted strong performance across key business segments, including APIs, formulations, and biologics. Management noted that the company achieved its highest quarterly revenue and EBITDA, with a consistent EBITDA margin of 30%. The document also mentioned a credit rating upgrade from A+ to AA-, indicating improved financial stability. Additionally, Shilpa Medicare is advancing its product pipeline, including a first-in-class treatment for Non-alcoholic Fatty Liver Disease and several biosimilars. The company emphasized its integrated approach to R&D and manufacturing, which has strengthened its market position and customer relationships.

Key takeaway: Shilpa Medicare Limited held its Q4 FY26 conference call on May 22, 2026, where management discussed the company's performance and future plans. CEO Keshav Bhutada highlighted that FY26 was a foundational year for the company, expanding its pharmaceutical platform across various segments, including complex APIs and biologics. The company reported its highest quarterly revenue of INR 439 crores, a 30% year-on-year increase, and a full-year revenue of INR 1,549 crores, growing 18%. EBITDA for Q4 was INR 121 crores, reflecting a 40% growth year-on-year. Management noted ongoing developments in their API and formulation segments, including new product launches and clinical studies. CFO Alpesh Dalal mentioned a reduction in interest outgo and an increase in net debt to INR 613 crores, attributed to business growth. The call concluded with management expressing confidence in sustaining growth and improving return ratios in the coming years.

Key takeaway: Shilpa Medicare Limited's investor presentation for the fourth quarter and financial year ended March 31, 2026, reported a revenue increase of 18% year-over-year, reaching INR 1,549 crores, with EBITDA growing by 30% to INR 445 crores. The presentation highlighted the company's diverse business segments, including API, Formulation, CDMO, and Biologics, and noted significant growth in the FDF and Biologics segments. Management emphasized the successful launch of NorUDCA for NAFLD, which has shown strong market traction. The presentation also detailed the company's robust R&D pipeline and strategic partnerships aimed at enhancing market share. Financial metrics indicated improved margins, with an EBITDA margin of 29% for FY26. The document concluded with a focus on future growth opportunities across various segments, including new product launches and regulatory filings.